Appointment dossier — Mucinous Ovarian Tumors
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Mucinous Ovarian Tumors
Compounds named in the cited literature for Mucinous Ovarian Tumors, labeled by the strongest evidence found:
- appendectomy — Named in the literature
- appendicectomy — Named in the literature
- capecitabine + oxaliplatin — Named in the literature
- carboplatin + paclitaxel — Named in the literature
- HER2-targeted therapy — Named in the literature
- PARP inhibitors — Named in the literature
- PD-1/PD-L1 inhibitors — Named in the literature
- primary cytoreductive surgery — Named in the literature
Open recruiting trials (18)
- NCT07488676 · Phase 1 / Phase 2 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (United States)
- NCT05512208 · Phase 2 — A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (United States)
- NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
- NCT06710756 · Phase 1 / Phase 2 — Lead-212 PSV359 Therapy for Patients With Solid Tumors (United States)
- NCT07760012 — 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors (China)
- NCT05349227 — Comprehensive Outcomes for After Cancer Health (United States)
- NCT05515354 · Phase 4 — Smoking Cessation and Menstrual Cycle Phase (Canada)
- NCT05606692 · Phase 4 — Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) (Taiwan)
- NCT05112601 · Phase 2 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (United States)
- NCT05123807 · Phase 2 — Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) (United States)
- NCT07067255 · Phase 1 / Phase 2 — Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer (China)
- NCT06395844 · Phase 1 / Phase 2 — Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer (China)
- NCT02073500 — Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies (Norway)
- NCT07339930 — Phenotyping of Patients With Polycystic Ovary Syndrome (France)
- NCT07403630 — INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) (Italy)
- NCT06564428 — A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration (China)
- NCT04251052 — A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (United States)
- NCT07290309 — Survivors Uniting for Remote Guided Exercise (United States)
Most-relevant first: trials that name Mucinous Ovarian Tumors, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT07488676), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?